Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Cancer Research|May 1, 1992
Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastasesJ B Tatro, Z Wen, M L Entwistle, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trialsM B Atkins, J Dutcher, G Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancyM B Atkins, G Vachino, H J Tilg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1994
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitroH Tilg, L Shapiro, E Vannier, et al.
Anti-Cancer Drugs|April 22, 1999
Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)H Hochster, M H Strawderman, J E Harris, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferonR K Alpaugh, M von Mehren, I Palazzo, et al.
Journal of Clinical Immunology|November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)M Allegretta, M B Atkins, R A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanomaD F McDermott, J W Mier, D P Lawrence, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Cancer Research|May 1, 1992
Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastasesJ B Tatro, Z Wen, M L Entwistle, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trialsM B Atkins, J Dutcher, G Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancyM B Atkins, G Vachino, H J Tilg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1994
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitroH Tilg, L Shapiro, E Vannier, et al.
Anti-Cancer Drugs|April 22, 1999
Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)H Hochster, M H Strawderman, J E Harris, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferonR K Alpaugh, M von Mehren, I Palazzo, et al.
Journal of Clinical Immunology|November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)M Allegretta, M B Atkins, R A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanomaD F McDermott, J W Mier, D P Lawrence, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
Pageof 11